ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP98-22 Commercial Pharmacy Benefit Exclusion for Cimerli™, Skysona®, Spevigo®, and Xenpozyme™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1131 - 1140 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP97-22 Update for New to Market Medical Drugs: etranacogene dezaparvovec
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP100-22 Service Area Expansion for Minnesota Health Care Programs (MHCP)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 23, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P25R1-20 Children’s Therapeutic Services and Supports (CTSS) Prior Authorization Requirement
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 01, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP112R1-20 Changes to Electronic Funds Transfer Processes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP11-23 Commercial Pharmacy Benefit Exclusion for Cimzia®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP12-23 Change in Prior Authorization Process for Experimental or Investigative Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 22, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-com-pharmprogpolicynotifctn-final-2.8.23-eff-4.1.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-final-eff-3.1.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP6-23 Commercial Pharmacy Benefit Exclusion for Briumvi™, Hemgenix®, Rebyota™, and Sunlenca® Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2023